RxDoctor Payments DataLook up a doctor →

William Shough

Medical · Martinsville, VANPI 1184060972

Payments from drug & device makers

$12,798in general payments, 2019–2025

Across 842 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$849
  • Lilly USA, LLC$780
  • Otsuka America Pharmaceutical, Inc.$749
  • AstraZeneca$627
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)149$2,210
Novo Nordisk80$1,177
Pfizer87$849
Lilly USA, LLC52$780
Otsuka America Pharmaceutical, Inc.42$749
AstraZeneca34$627
Amgen37$530
GSK28$466
Lundbeck LLC25$376
Takeda Pharmaceuticals U.S.A., Inc.20$353
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$314
Mylan Specialty L.p.17$314
Boehringer Ingelheim18$276
Abbott15$270
Johnson & Johnson17$260
Merck17$254
Bayer13$225
E.r. Squibb & Sons, L.L.C.12$185
Dexcom, Inc.10$177
Currax Pharmaceuticals LLC11$173
Biohaven Pharmaceutical Holding Company Ltd.13$159
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$141
Phathom Pharmaceuticals, Inc.8$141
Ardelyx, Inc.7$129
Astellas Pharma US Inc7$117
Nestle Healthcare Nutrition Inc.7$116
Aimmune Therapeutics, Inc.6$109
Vanda Pharmaceuticals Inc.5$106
Ironwood Pharmaceuticals, Inc7$100
Novartis5$80
Sunovion Pharmaceuticals Inc.5$77
Biogen5$75
Biohaven Pharmaceuticals, Inc.3$74
Sanofi-aventis U.S. LLC5$68
Esperion Therapeutics, Inc.4$66
Eisai Inc.4$51
Idorsia Pharmaceuticals US Inc3$46
Seqirus USA Inc3$45
Alkermes, Inc.2$43
Corium, LLC3$43
Medtronic3$40
Exact Sciences2$33
Impel Pharmaceuticals Inc.2$33
Xeris Pharmaceuticals, Inc.2$32
Phadia US Inc.2$30
Amarin Pharma, Inc.2$28
Kowa Pharmaceuticals America, Inc.2$28
Axonics, Inc.2$28
ARS Pharmaceuticals Operations, Inc.1$23
Axsome Therapeutics, Inc.1$18
Lexicon Pharmaceuticals, Inc.1$18
Insulet Corporation1$17
Genentech USA, Inc.1$17
Tandem Diabetes Care, Inc.1$17
Organon1$16
Kaleo, Inc.1$14
Sanofi Pasteur Inc.1$14
Vifor Pharma, Inc.1$12
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$11
Supernus Pharmaceuticals, Inc.1$11

How this compares

$12,798 in reported general payments places this provider in the 95th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$66,997
Medicare patients
258
Services billed
3,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$116,692
EliquisApixaban92$116,458
FarxigaDapagliflozin Propanediol104$111,990
JardianceEmpagliflozin80$107,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$101,585
TrulicityDulaglutide67$90,532
Soliqua 100-33Insulin Glargine/Lixisenatide49$69,008
JanuviaSitagliptin Phosphate63$58,241
LinzessLinaclotide54$53,387
Tresiba Flextouch U-200Insulin Degludec41$49,795
EntrestoSacubitril/Valsartan43$46,018
Breo ElliptaFluticasone/Vilanterol93$41,144
XifaxanRifaximin13$40,365
MounjaroTirzepatide18$30,497
VraylarCariprazine Hcl20$28,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$466$162,672266 claims
PfizerEliquis, Nurtec Odt$849$141,438107 claims
AstraZenecaFarxiga, Symbicort$627$124,017131 claims
Lilly USA, LLCTrulicity, Mounjaro$780$121,03085 claims
Novo NordiskOzempic$1,177$116,69290 claims
Boehringer IngelheimJardiance, Tradjenta$276$113,62492 claims
AbbVieLinzess, Vraylar$2,210$81,51974 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$68$69,00849 claims
MerckJanuvia$254$58,24163 claims
NovartisEntresto$80$46,01843 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$314$40,36513 claims
Otsuka America Pharmaceutical, Inc.Rexulti$749$28,05019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 632 medical providers in Virginia.

Other medical in Martinsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →